Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
Authors:
- Karin A van GarderenKGKarin A van Garderen
- Wies R VallentgoedWVWies R Vallentgoed
- Anna LavrovaALAnna Lavrova
- Johanna M NiersJNJohanna M Niers
- Wendy W J de LengWLWendy W J de Leng
- Youri HoogstrateYHYouri Hoogstrate
- Iris de HeerIHIris de Heer
- Bauke YlstraBYBauke Ylstra
- Erik van DijkEDErik van Dijk
- Stefan KleinSKStefan Klein
- Kaspar DraaismaKDKaspar Draaisma
- Pierre A J T RobePRPierre A J T Robe
Open Access
- 1 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 5 (1) , vdad149
Abstract
Background: The T2-FLAIR mismatch sign is defined by signal loss of the T2-weighted hyperintense area with Fluid-Attenuated Inversion Recovery (FLAIR) on magnetic resonance imaging, causing a hypointense region on FLAIR. It is a highly specific diagnostic marker for IDH-mutant astrocytoma and is postulated to be caused by intercellular microcystic change in the tumor tissue. However, not all IDH-mutant astrocytomas show this mismatch sign and some show the phenomenon in only part of the lesion. The aim of the study is to determine whether the T2-FLAIR mismatch phenomenon has any prognostic value beyond initial noninvasive molecular diagnosis. Methods: Patients initially diagnosed with histologically lower-grade (2 or 3) IDH-mutant astrocytoma and with at least 2 surgical resections were included in the GLASS-NL cohort. T2-FLAIR mismatch was determined, and the growth pattern of the recurrent tumor immediately before the second resection was annotated as invasive or expansive. The relation between the T2-FLAIR mismatch sign and tumor grade, microcystic change, overall survival (OS), and other clinical parameters was investigated both at first and second resection. Results: The T2-FLAIR mismatch sign was significantly related to Grade 2 (80% vs 51%), longer post-resection median OS (8.3 vs 5.2 years), expansive growth, and lower age at second resection. At first resection, no relation was found between the mismatch sign and OS. Microcystic change was associated with areas of T2-FLAIR mismatch. Conclusions: T2-FLAIR mismatch in IDH-mutant astrocytomas is correlated with microcystic change in the tumor tissue, favorable prognosis, and Grade 2 tumors at the time of second resection.Keywords
Funding Information
- Dutch Cancer Society (KWF 11026)
- Medical Delta
This publication has 16 references indexed in Scilit:
- “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomasNeuro-Oncology, 2020
- Selective and Recyclable Congo Red Dye Adsorption by Spherical Fe3O4 Nanoparticles Functionalized with 1,2,4,5-Benzenetetracarboxylic AcidScientific Reports, 2020
- Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective studyThe Lancet Oncology, 2019
- The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation studyNeuro-Oncology, 2018
- Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis ConsortiumNeuro-Oncology, 2018
- T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA ProjectClinical Cancer Research, 2017
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patientsJournal Of Neuroradiology, 2015
- User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliabilityNeuroImage, 2006
- Neurosurgical Outcomes in a Modern Series of 400 Craniotomies for Treatment of Parenchymal TumorsNeurosurgery, 1998